Biomed Pharmacother
Biomedicine & Pharmacotherapy, abbreviated as Biomed Pharmacother, is a premier international peer-reviewed journal dedicated to advancing the understanding and application of biomedical and pharmacological sciences. With an ISSN of 0753-3322 and a notable 2026 Impact Factor of 7.5000, the journal holds a distinguished Q1 ranking in its JCR quartile, reflecting its high citation impact and influential position within the field. The journal’s scope encompasses a broad spectrum of topics, including cellular and molecular biology, pharmacology, toxicology, drug discovery and development, clinical pharmacotherapy, and the mechanisms underlying disease pathogenesis and treatment. It particularly welcomes studies on cancer biology, cardiovascular and neurological disorders, infectious diseases, and the pharmacological effects of natural products and synthetic compounds. Biomedicine & Pharmacotherapy publishes a variety of article types, including original research articles, comprehensive reviews, short communications, and case reports, all of which undergo rigorous single-blind peer review to ensure scientific validity and novelty. The target audience includes academic researchers, clinical pharmacologists, pharmaceutical scientists, toxicologists, and healthcare professionals seeking cutting-edge insights into therapeutic interventions and disease management. A key distinguishing feature is the journal’s open access model, which ensures that all published content is freely available online, thereby maximizing global dissemination and impact. Published by Elsevier, a leading scientific publisher, the journal is indexed in major databases such as PubMed, Scopus, and Web of Science, and its consistent Q1 standing underscores its reputation as a high-quality, authoritative resource for interdisciplinary research bridging laboratory discoveries and clinical applications.